News

Stifel Maintains Buy Rating on Nurix (NRIX) Stock
Stifel Nicolaus analyst Stephen Willey maintained a Buy rating on Nurix Therapeutics, Inc. (NASDAQ:NRIX) with a price target ...
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout
Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a ...
Nasdaq4d
Sanofi To Acquire Blueprint Medicines In $9.5 Bln Deal
Sanofi will launch a cash tender offer for Blueprint ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...
Morgan Stanley Resumes Sanofi (SNY) Coverage, Assigns Equal Weight Rating
Morgan Stanley analyst Sarita Kapila resumed coverage of Sanofi (NASDAQ:SNY), assigning an Equal Weight rating and setting a ...
Sanofi, Regeneron fall after late-stage data for COPD therapy
Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) traded sharply lower in the premarket on Friday after the companies announced ...
Nasdaq7d
Regeneron and Sanofi Announce Mixed Results from Phase 3 AERIFY Trials for Itepekimab in COPD Patients
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. Regeneron Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and ...
Citizens JMP Downgrades Blueprint Medicines (BPMC) to Market Perform
Citizens JMP analyst Reni Benjamin downgraded Blueprint Medicines Corporation (NASDAQ:BPMC) to Market Perform from Outperform ...
Sanofi to buy US blood disorder drugmaker for up to $9.5bn
Sanofi will buy the US maker of the world’s only approved treatment for a debilitating rare blood disorder for up to $9.5bn, as it seeks to boost its immunology medicine pipeline.